Literature DB >> 458431

Dopamine-sensitive adenylate cyclase activity in the striatum in Parkinson's disease.

M Shibuya.   

Abstract

Dopamine (DA) sensitive adenylate cyclase activity was measured in homogenates of caudate nucleus and putamen from frozen brain of eight Parkinsonian patients and nine controls. In the control group, there was no difference in enzyme activity in respect to sex or age (21--77 years old). Caudate nucleus and putamen exhibited similar mean activity. In the Parkinsonian group, there was a significant decrease in both basal (by 50%) and DA stimulated (by 80%) activities compared with that of control group. This suggests that there may exist a functional disturbance in the postsynaptic (post-DA-nergic) region in the striatum of patients with Parkinson's disease; in addition, the decrease in basal as well as DA stimulated activity as measured in homogenates may not be the biochemical substrate for the hypothetical "denervation supersensitivity" expected to occur in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 458431     DOI: 10.1007/bf01250323

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  21 in total

1.  Modulator binding protein. Bovine brain protein exhibiting the Ca2+-dependent association with the protein modulator of cyclic nucleotide phosphodiesterase.

Authors:  J H Wang; R Desai
Journal:  J Biol Chem       Date:  1977-06-25       Impact factor: 5.157

2.  Stimulation by dopamine of adenosine cyclic 3',5'-monophosphate formation in rat caudate nucleus: effect of lesions of the nigro-neostriatal pathway.

Authors:  B K Krueger; J Forn; J R Walters; R H Roth; P Greengard
Journal:  Mol Pharmacol       Date:  1976-07       Impact factor: 4.436

3.  Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea.

Authors:  P L McGeer; E G McGeer
Journal:  J Neurochem       Date:  1976-01       Impact factor: 5.372

4.  Cyclic 3',5'-nucleotide phosphodiesterase. Demonstration of an activator.

Authors:  W Y Cheung
Journal:  Biochem Biophys Res Commun       Date:  1970-02-06       Impact factor: 3.575

5.  Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

Authors:  J W Kebabian; G L Petzold; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1972-08       Impact factor: 11.205

6.  L-glutamic acid decarboxylase in Parkinson's disease: effect of L-dopa therapy.

Authors:  K G Lloyd; O Hornykiewicz
Journal:  Nature       Date:  1973-06-29       Impact factor: 49.962

Review 7.  Parkinson's disease: from brain homogenate to treatment.

Authors:  O Hornykiewicz
Journal:  Fed Proc       Date:  1973-02

8.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1961-11-10       Impact factor: 1.704

9.  Enhancement of dopamine-stimulated adenylate cyclase activity in rat caudate after lesions in substantia nigra: evidence for denervation supersensitivity.

Authors:  R K Mishra; E L Gardner; R Katzman; M H Makman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

10.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15
View more
  6 in total

1.  Neurotransmitter-mediated inhibition of post-mortem human brain adenylyl cyclase.

Authors:  A Garlind; C J Fowler; I Alafuzoff; B Winblad; R F Cowburn
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.

Authors:  M Rodriguez; G Lera; J Vaamonde; M R Luquin; J A Obeso
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

3.  6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.

Authors:  G R Breese; G E Duncan; T C Napier; S C Bondy; L C Iorio; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

4.  Dopamine receptors in the Parkinsonian brain.

Authors:  U K Rinne; P Lönnberg; V Koskinen
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

5.  Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.

Authors:  K Jellinger
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

6.  Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms.

Authors:  J Balldin; A K Granérus; G Lindstedt; K Modigh; J Wålinder
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.